Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ZNF536 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA520854
Description
A suggested positive control is human brain tissue lysate. PA5-20854 can be used with blocking peptide PEP-0968.
ZNF536 is a recently identified zinc-finger protein that is expressed primarily in the developing nervous system and the cerebral cortex, hippocampus, and hypothalamus. ZNF536 possess ten zinc fingers and interacts with CtBP1, a corepressor for gene transcription. It is most closely related to transcriptional repressor ZNF219. Overexpression of ZNF536 in embryonic stem cells dramatically reduced the mRNA levels of neuronal marker genes such as Pax6, MAP2, and beta-tubulin III following retinoic acid (RA)-induced differentiation, while depletion of ZNF536 via RNAi resulted in elevated mRNA levels of these genes, indicating its role in inhibiting neuronal cell differentiation. Overexpression of RA receptor a rescues the inhibitory role of ZNF536, suggesting that ZNF536 might inhibit RA response element-mediated transcriptional activity.
Specifications
ZNF536 | |
Polyclonal | |
Unconjugated | |
ZNF536 | |
9630010P11Rik; KIAA0390; mKIAA0390; RGD1563363; Zfp536; Zinc finger protein 536; Znf536 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
243937, 292820, 9745 | |
Maintain refrigerated at 2°C to 8°C for up to 3 months. For long term storage store at -20°C | |
Liquid |
Immunohistochemistry, Western Blot | |
1 mg/mL | |
PBS with 0.02% sodium azide | |
O15090, Q8K083 | |
Zfp536, ZNF536 | |
A 16 amino acid peptide from near the amino terminus of human ZNF536. | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction